Tempest Therapeutics Reports Critical Q1 Loss, Low Cash, Despite Strong Clinical Data

summarizeSummary

Tempest Therapeutics reported a significant net loss of $27.7 million for Q1 2026, reducing cash to $1.8 million, highlighting severe financial distress despite announcing positive clinical data for its lead CAR-T therapy, TPST-2003.

check_boxKey Events

• Critical Cash Position

  Cash and cash equivalents plummeted to $1.8 million as of March 31, 2026, down from $7.7 million at year-end 2025.

• Significant Net Loss

  Reported a net loss of $27.7 million for Q1 2026, a substantial increase from $10.9 million in Q1 2025.

• Positive Clinical Data for TPST-2003

  Announced a 100% complete response (CR) rate among 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 across two ongoing clinical trials, with a favorable safety profile.

• Manufacturing Partnership Secured

  Selected Cincinnati Children's Applied Gene and Cell Therapy Center (AGCTC) as the lead manufacturing partner for TPST-2003, supporting plans to initiate a potentially registrational study later this year.

auto_awesomeAnalysis

The company's Q1 2026 financial results reveal a critical cash position, with only $1.8 million remaining and a net loss of $27.7 million for the quarter, which is nearly its entire market capitalization. This severe cash burn raises immediate concerns about the company's ability to continue operations, as also indicated by the 'going concern' language in its forward-looking statements. While the positive interim clinical data for TPST-2003 (100% complete response rate) is a significant scientific achievement and offers a potential path to value, the company faces an urgent need for substantial capital to fund its programs and address its liquidity crisis.